- Home
- LEA vs MDGL Comparison
LEA vs MDGL Comparison
Compare LEA & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEA
- MDGL
- Stock Information
- Founded
- LEA 1917
- MDGL 2011
- Country
- LEA United States
- MDGL United States
- Employees
- LEA N/A
- MDGL N/A
- Industry
- LEA Auto Parts:O.E.M.
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- LEA Consumer Discretionary
- MDGL Health Care
- Exchange
- LEA Nasdaq
- MDGL Nasdaq
- Market Cap
- LEA 5.6B
- MDGL 6.1B
- IPO Year
- LEA N/A
- MDGL N/A
- Fundamental
- Price
- LEA $105.90
- MDGL $417.43
- Analyst Decision
- LEA Buy
- MDGL Strong Buy
- Analyst Count
- LEA 11
- MDGL 10
- Target Price
- LEA $115.27
- MDGL $474.67
- AVG Volume (30 Days)
- LEA 587.4K
- MDGL 329.8K
- Earning Date
- LEA 10-23-2025
- MDGL 10-30-2025
- Dividend Yield
- LEA 2.91%
- MDGL N/A
- EPS Growth
- LEA N/A
- MDGL N/A
- EPS
- LEA 8.57
- MDGL N/A
- Revenue
- LEA $22,889,700,000.00
- MDGL $515,547,000.00
- Revenue This Year
- LEA N/A
- MDGL $394.12
- Revenue Next Year
- LEA $2.13
- MDGL $57.74
- P/E Ratio
- LEA $12.35
- MDGL N/A
- Revenue Growth
- LEA N/A
- MDGL 3421.98
- 52 Week Low
- LEA $73.85
- MDGL $200.63
- 52 Week High
- LEA $115.47
- MDGL $457.16
- Technical
- Relative Strength Index (RSI)
- LEA 48.93
- MDGL 54.19
- Support Level
- LEA $103.58
- MDGL $418.36
- Resistance Level
- LEA $111.87
- MDGL $440.90
- Average True Range (ATR)
- LEA 2.67
- MDGL 13.63
- MACD
- LEA -0.88
- MDGL -5.66
- Stochastic Oscillator
- LEA 24.34
- MDGL 4.56
About LEA Lear Corporation
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.